Clinical Overview > Hormone > Normetanephrine

You are looking at 11 - 15 of 15 items

Run Yu Division of Endocrinology, Diabetes, and Metabolism, UCLA David Geffen School of Medicine, Los Angeles, USA

Search for other papers by Run Yu in
Google Scholar
PubMed
Close
,
Danielle Sharaga Cancer Center of Santa Barbara with Sansum Clinic, Santa Barbara, California, USA

Search for other papers by Danielle Sharaga in
Google Scholar
PubMed
Close
,
Christopher Donner Sansum Clinic, Santa Barbara, California, USA

Search for other papers by Christopher Donner in
Google Scholar
PubMed
Close
,
M Fernando Palma Diaz Department of Pathology

Search for other papers by M Fernando Palma Diaz in
Google Scholar
PubMed
Close
,
Masha J Livhits Section of Endocrine Surgery, UCLA David Geffen School of Medicine, Los Angeles, USA

Search for other papers by Masha J Livhits in
Google Scholar
PubMed
Close
, and
Michael W Yeh Section of Endocrine Surgery, UCLA David Geffen School of Medicine, Los Angeles, USA

Search for other papers by Michael W Yeh in
Google Scholar
PubMed
Close

Summary

Pheochromocytomatosis, a very rare form of pheochromocytoma recurrence, refers to new, multiple, and often small pheochromocytomas growing in and around the surgical resection bed of a previous adrenalectomy for a solitary pheochromocytoma. We here report a case of pheochromocytomatosis in a 70-year-old female. At age 64 years, she was diagnosed with a 6-cm right pheochromocytoma. She underwent laparoscopic right adrenalectomy, during which the tumor capsule was ruptured. At age 67 years, CT of abdomen did not detect recurrence. At age 69 years, she began experiencing episodes of headache and diaphoresis. At age 70 years, biochemical markers of pheochromocytoma became elevated with normal calcitonin level. CT revealed multiple nodules of various sizes in the right adrenal fossa, some of which were positive on metaiodobenzylguanidine (MIBG) scan. She underwent open resection of pheochromocytomatosis. Histological examination confirmed numerous pheochromocytomas ranging 0.1–1.2 cm in size. Next-generation sequencing of a panel of genes found a novel heterozygous germline c.570delC mutation in TMEM127, one of the genes that, if mutated, confers susceptibility to syndromic pheochromocytoma. Molecular analysis showed that the c.570delC mutation is likely pathogenic. Our case highlights the typical presentation of pheochromocytomatosis, a rare complication of adrenalectomy for pheochromocytoma. Previous cases and ours collectively demonstrate that tumor capsule rupture during adrenalectomy is a risk factor for pheochromocytomatosis. We also report a novel TMEM127 mutation in this case.

Learning points:

  • Pheochromocytomatosis is a very rare form of pheochromocytoma recurrence.

  • Pheochromocytomatosis refers to new, multiple and often small pheochromocytomas growing in and around the surgical resection bed of a previous adrenalectomy for a solitary pheochromocytoma.

  • Tumor capsule rupture during adrenalectomy predisposes a patient to develop pheochromocytomatosis.

  • Surgical resection of the multiple tumors of pheochromocytomatosis is recommended.

  • Pheochromocytoma recurrence should prompt genetic testing for syndromic pheochromocytoma.

Open access
Kohei Saitoh Departments of Diabetes and Endocrinology

Search for other papers by Kohei Saitoh in
Google Scholar
PubMed
Close
,
Takako Yonemoto Departments of Diabetes and Endocrinology
Medical Genetics, Shizuoka General Hospital, Shizuoka, Japan

Search for other papers by Takako Yonemoto in
Google Scholar
PubMed
Close
,
Takeshi Usui Medical Genetics, Shizuoka General Hospital, Shizuoka, Japan

Search for other papers by Takeshi Usui in
Google Scholar
PubMed
Close
,
Kazuhiro Takekoshi Division of Sports Science, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan

Search for other papers by Kazuhiro Takekoshi in
Google Scholar
PubMed
Close
,
Makoto Suzuki Departments of Pathology

Search for other papers by Makoto Suzuki in
Google Scholar
PubMed
Close
,
Yoshiharu Nakashima Departments of Urology, Shizuoka General Hospital, Shizuoka, Japan

Search for other papers by Yoshiharu Nakashima in
Google Scholar
PubMed
Close
,
Koji Yoshimura Departments of Urology, Shizuoka General Hospital, Shizuoka, Japan

Search for other papers by Koji Yoshimura in
Google Scholar
PubMed
Close
,
Rieko Kosugi Departments of Diabetes and Endocrinology

Search for other papers by Rieko Kosugi in
Google Scholar
PubMed
Close
,
Tatsuo Ogawa Departments of Diabetes and Endocrinology

Search for other papers by Tatsuo Ogawa in
Google Scholar
PubMed
Close
, and
Tatsuhide Inoue Departments of Diabetes and Endocrinology

Search for other papers by Tatsuhide Inoue in
Google Scholar
PubMed
Close

Summary

Pheochromocytomas (PCCs) and paragangliomas (PGLs) are rare tumours with a heterogeneous genetic background. Up to 40% of apparently sporadic PCC/PGL cases carry 1 of the 12 gene germline mutations conferring genetic susceptibility to PCC/PGL. Although the precise mechanisms are unclear, TMEM127 is one of the rare responsible genes for PCC/PGL. Here we report the case of a patient with familial PCC having a novel TMEM127 variant (c.119C > T, p.S40F). In silico prediction analysis to evaluate the functional significance of this variant suggested that it is a disease-causing variant. A PCC on the left side was considered to be the dominant lesion, and unilateral adrenalectomy was performed. The histopathologic findings were consistent with benign PCC. A loss of heterogeneity of the TMEM127 variant was detected in the surgically removed tumour.

Learning points:

  • c.119C > T (p.S40F) is a novel TMEM127 variant that can cause pheochromocytoma.

  • The tumour showed loss of heterozygosity of this TMEM127 variant.

  • The clinical phenotype of this mutation is putative bilateral pheochromocytoma in the 4th decade.

  • Unilateral adrenalectomy may be performed as the initial surgery in such cases.

Open access
Rowena Speak Departments of Oncology and Metabolism, University of Sheffield

Search for other papers by Rowena Speak in
Google Scholar
PubMed
Close
,
Jackie Cook Department of Genetics, Sheffield Children’s Hospital, Sheffield, UK

Search for other papers by Jackie Cook in
Google Scholar
PubMed
Close
,
Barney Harrison Endocrine Surgery, Royal Hallamshire Hospital, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK

Search for other papers by Barney Harrison in
Google Scholar
PubMed
Close
, and
John Newell-Price Departments of Oncology and Metabolism, University of Sheffield
Endocrinology

Search for other papers by John Newell-Price in
Google Scholar
PubMed
Close

Mutations of the rearranged during transfection (RET) proto-oncogene, located on chromosome 10q11.2, cause multiple endocrine neoplasia type 2A (MEN2A). Patients with mutations at the codon 609 usually exhibit a high penetrance of medullary thyroid cancer (MTC), but a sufficiently low penetrance of phaeochromocytoma that screening for this latter complication has been called to question. Patients with other RET mutations are at higher risk of younger age onset phaeochromocytoma if they also possess other RET polymorphisms (L769L, S836S, G691S and S904S), but there are no similar data for patients with 609 mutations. We investigated the unusual phenotypic presentation in a family with MEN2A due to a C609Y mutation in RET. Sanger sequencing of the entire RET-coding region and exon–intron boundaries was performed. Five family members were C609Y mutation positive: 3/5 initially presented with phaeochromocytoma, but only 1/5 had MTC. The index case aged 73 years had no evidence of MTC, but presented with phaeochromocytoma. Family members also possessed the G691S and S904S RET polymorphisms. We illustrate a high penetrance of phaeochromocytoma and low penetrance of MTC in patients with a RET C609Y mutation and polymorphisms G691S and S904S. These data highlight the need for life-long screening for the complications of MEN2A in these patients and support the role for the screening of RET polymorphisms for the purposes of risk stratification.

Learning points:

  • C609Y RET mutations may be associated with a life-long risk of phaeochromocytoma indicating the importance of life-long screening for this condition in patients with MEN2A.

  • C609Y RET mutations may be associated with a lower risk of MTC than often quoted, questioning the need for early prophylactic thyroid surgery discussion at the age of 5 years.

  • There may be a role for the routine screening of RET polymorphisms, and this is greatly facilitated by the increasing ease of access to next-generation sequencing.

Open access
Annika Sjoeholm Department of Women's and Children's Health, University of Otago, Dunedin School of Medicine, PO Box 56, Dunedin 9054, New Zealand

Search for other papers by Annika Sjoeholm in
Google Scholar
PubMed
Close
,
Cassandra Li Department of Women's and Children's Health, University of Otago, Dunedin School of Medicine, PO Box 56, Dunedin 9054, New Zealand

Search for other papers by Cassandra Li in
Google Scholar
PubMed
Close
,
Chaey Leem Department of Women's and Children's Health, University of Otago, Dunedin School of Medicine, PO Box 56, Dunedin 9054, New Zealand

Search for other papers by Chaey Leem in
Google Scholar
PubMed
Close
,
Aiden Lee Department of Women's and Children's Health, University of Otago, Dunedin School of Medicine, PO Box 56, Dunedin 9054, New Zealand

Search for other papers by Aiden Lee in
Google Scholar
PubMed
Close
,
Maria P Stack Paediatric Nephrology, Starship Children's Hospital, Auckland, New Zealand

Search for other papers by Maria P Stack in
Google Scholar
PubMed
Close
,
Paul L Hofman Liggins Institute, University of Auckland, Auckland, New Zealand

Search for other papers by Paul L Hofman in
Google Scholar
PubMed
Close
, and
Benjamin J Wheeler Department of Women's and Children's Health, University of Otago, Dunedin School of Medicine, PO Box 56, Dunedin 9054, New Zealand
Paediatric Endocrinology, Southern District Health Board, Dunedin, New Zealand

Search for other papers by Benjamin J Wheeler in
Google Scholar
PubMed
Close

Summary

Phaeochromocytomas are a rare clinical entity, with dual hormone-secreting lesions particularly uncommon, seen in <1%. ACTH is the most common hormone co-produced, and is potentially lethal if not diagnosed. We present the case of a previously well 10-year-old boy, who presented acutely with a hypertensive crisis and was found to have a unilateral, non-syndromic phaeochromocytoma. Medical stabilization of his hypertension was challenging, and took 3 weeks to achieve, before proceeding to unilateral adrenalectomy. Post-operatively the child experienced severe fatigue and was subsequently confirmed to have adrenal insufficiency. He improved markedly with hydrocortisone replacement therapy, which is ongoing 6 months post-operatively. In retrospect this likely represents unrecognized, sub-clinical ACTH-dependent Cushing's syndrome secondary to an ACTH/or precursor dual-hormone secreting phaeochromocytoma. At follow-up, his hypertension had resolved, there was no biochemical evidence of recurrence of the phaeochromocytoma, and genetic analysis was indicative of a sporadic lesion.

Learning points

  • Dual hormone secreting phaeochromocytomas with ACTH/or a precursor may cause secondary adrenal insufficiency following surgical removal.

  • The concurrent features of Cushing's syndrome can be mild and easily overlooked presenting diagnostic and management pitfalls.

  • As concomitant syndromes of hormone excess are rare in phaeochromocytomas; the diagnosis requires a high index of suspicion.

  • Serial/diurnal cortisol levels, ACTH measurement +/− low dose dexamethasone suppression (when clinically stable, appropriate adrenergic blockade in place, and well supervised), can all be considered as needed.

Open access
C Mumby
Search for other papers by C Mumby in
Google Scholar
PubMed
Close
,
J R E Davis
Search for other papers by J R E Davis in
Google Scholar
PubMed
Close
,
J Trouillas Department of Histology and Molecular Embryology, Université de Lyon, Lyon, France

Search for other papers by J Trouillas in
Google Scholar
PubMed
Close
, and
C E Higham Department of Endocrinology, Christie Hospital NHS Foundation Trust, Manchester, UK

Search for other papers by C E Higham in
Google Scholar
PubMed
Close

Summary

A 52-year-old lady was referred after a 5 cm left adrenal mass was detected on computed tomography (CT) scanning. She was asymptomatic although was noted to have acromegalic facies. Blood pressure (BP) was normal but plasma normetanephrines were raised to 2.81 mmol/l (<1.09) and urinary normetadrenaline excretion 5.3 μmol/24 h (0–4.3). Adrenal biochemistry screen was otherwise normal. Metaiodobenzylguanidine (MIBG) scan demonstrated uptake in the adrenal lesion. Growth hormone (GH) nadir on oral glucose tolerance test (OGTT) was 2.2 ng/ml with an elevated IGF1 level of 435 ng/ml (72–215), confirming acromegaly biochemically. The remainder of the pituitary screen was normal. A magnetic resonance imaging (MRI) scan of the pituitary revealed an enlarged pituitary gland with a microadenoma/cyst of 2–3 mm in diameter. Alpha blockade was achieved with a titrated dose of phenoxybenzamine before a successful laparoscopic hand-assisted left adrenalectomy. Postoperative biochemical testing revealed a normal plasma normetanephrine level of 0.6 nmol/l (<1.09) and a metanephrine level of 0.35 nmol/l (<0.46 nmol/l). Nadir on OGTT was normal at 0.07 ng/ml with an IGF1 level within the reference range at 111 ng/ml (75–215). Histology demonstrated a well-circumscribed and encapsulated oval mass with microscopic features typical for a phaeochromocytoma. The sections stained strongly positive for GHRH in 20% of cells on immunocytochemistry. Genetic analysis showed no pathogenic mutation. This is a report of the rare condition of a phaeochromocytoma co-secreting GHRH resulting in clinical and biochemical acromegaly. Neuroendocrine tumours can stain positive for GHRH without coexisting acromegaly, but the resolution of patient symptoms and normalisation of serum GH and IGF1 levels following surgery imply that this was functional secretion. Pituitary surgery should be avoided in such cases.

Learning points

  • Incidental findings on imaging require thorough investigation to determine the presence of serious pathology.

  • Acromegaly and phaeochromocytoma are rarely coincident in the same patient. If this occurs, co-secretion of GHRH from the phaeochromocytoma or the presence of underlying genetic abnormalities must be considered.

  • Acromegaly is due to ectopic GHRH-secreting neuroendocrine tumours in <1% of cases, most commonly pancreatic or bronchial lesions.

  • Co-secretion of GHRH from a phaeochromocytoma is extremely rare.

  • In such cases, the pituitary gland may appear enlarged but pituitary surgery should be avoided and surgical treatment of the neuroendocrine tumour attempted.

Open access